Evidence map›Paper›PMID 40289198›Full record

ArticleScientific reports2025

Metabolic profiling and antibacterial activity of secondary metabolites extracted from the endophytic bacteria of Combretum erythrophyllum.

Olufunto T Fanoro, Oluwatobi S Oluwafemi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olufunto T FanoroCentre for Nanomaterials Sciences Research, University of Johannesburg, Johannesburg, 2028, South Africa.
Oluwatobi S OluwafemiCentre for Nanomaterials Sciences Research, University of Johannesburg, Johannesburg, 2028, South Africa. oluwafemi.oluwatobi@gmail.com.

Funding

National Research Foundation (N.R.F), South Africa under the Competitive Programme for Rated Researchers (CPRR). Grant no: 129290
6 · The paper itself

Abstract

Antibiotic resistance continues to pose a significant global challenge associated with increased rates of illness and death. The emergence of multidrug resistance patterns in pathogenic bacteria poses a challenge in their treatment, rendering them unmanageable with traditional antibiotics in the foreseeable future. Thus, prioritising innovative pharmaceuticals for therapy and exploring alternate approaches to combat antimicrobial resistance is of utmost importance. Endophytic bacteria derived from medicinal plants are reservoirs of active therapeutic compounds, offering a promising alternative for discovering novel and therapeutically bioactive compounds. This work involved the isolation and identification of four endophytic bacteria from Combretum erythrophyllum. The antibacterial activity and metabolic profiling of the secondary metabolite extract were assessed via the microdilution technique and gas chromatography data analysis, respectively. The assessed extract showed wide-ranging effectiveness against Gram-positive and Gram-negative bacteria, with a particular preference for Klebsiella aerogenes (ATCC 27853) at a minimum inhibitory concentration of 125 µg/mL. The analysed secondary metabolites revealed phytochemicals, namely terpenoids, ketones, phytosterols, phenols, alkanes, and fatty acid methyl esters (FAME) as the bioactive constituents. In conclusion, this study underscores the importance of the endophytic bacteria of C. erythrophyllum as a potential source of active natural bioactive compounds for antibiotic therapy.

Indexed as

Anti-Bacterial AgentsBacteriaCombretumEndophytesMetabolomeSecondary MetabolismGram-Negative BacteriaGram-Positive BacteriaMetabolomicsMicrobial Sensitivity TestsPhytochemicalsAnti-Bacterial AgentsPhytochemicalsAntibioticsCombretum erythrophyllumEndophytesKlebsiella aerogenesSecondary metabolites

Identifiers

PMID40289198
PMCPMC12034791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.